Where does the world stand in the fight against HIV and AIDS?

In the fight to end the HIV and AIDS epidemic, a small window of opportunity is opening. Efforts have almost reached the half-way point for ending the disease: the number of those in treatment, 1.7 million people, is on track to surpass the number of new annual infections, about 2 million, by next year. The time is therefore ripe for reassessing what works, what doesn’t, and where financing will come from to get and stay ahead of HIV and AIDS.

Devex spoke with Erin Hohlfelder, head of global health policy at the ONE Campaign about the most promising financing tools on the HIV and AIDS front, how the indicators for the Sustainable Development Goals and new financing trends can shape the donor landscape, and how organizations are adapting to the rapidly shifting need to reach the most marginalized populations.

Here are some highlights from that conversation:

What’s changed in the funding landscape for efforts against AIDS since 2000? What are the new challenges in battling donor complacency?

We know infectious diseases don’t wait around for opportune political moments, they will continue to spread if they’re not effectively targeted. And that’s the same for HIV, malaria, and even we saw in cases like Ebola. If donors get complacent or delay funding disbursements, we allow situations to get out of control and ultimately cost us a lot more money to fix than if we had addressed them head on.

One way to do this is to look at the health budgets not just for donor countries, but recipient countries as well. We then [compare that to] development assistance writ large, and in our report we look at African country spending on health writ large as well. We don’t think it’s right to just fight for AIDS funding or just fight for malaria funding if it robs Peter to pay Paul. We want to tackle disease intervention in a holistic way.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below